The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
How does deucravacitinib fit into the treatment landscape for plaque psoriasis?
Featured:
Paolo Gisondi
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
What is the mechanism of action of deucravacitinib?
A
B
C
D
The Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Paolo Gisondi, University Hospital of Verona, Verona, IT. We asked, How does deucravacitinib fit into the treatment landscape for plaque psoriasis?
How does deucravacitinib fit into the treatment landscape for plaque psoriasis?
Gisondi discusses the benefit of oral therapies, such as deucravacitinib, as a more convenient and patient-friendly treatment option than injectable treatments. He highlights that injectable therapies can be intimidating for patients who are starting a new systemic treatment, then goes on to discuss the efficacy and, in particular, the safety benefit of deucravacitinib due to its allosteric inhibition of tyrosine kinase 2 (TYK2), when compared with Janus kinase (JAK) inhibitors. He emphasizes the reduced risk of infections, such as upper respiratory tract infections or nasopharyngitis, in patients treated with deucravacitinib vs JAK inhibitors. Finally, he discusses the potential of deucravacitinib in patients with psoriasis with characteristics of eczema, and in patients who had paradoxical eczema reactions to interleukin-17 (IL-17) inhibitors.
This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content